Research progress in ferroptosis regulation in the treatment of liver diseases

doi:10.3969/j.issn.1674-8115.2023.03.013

Abstract

Abstract:

Ferroptosis is a form of cell death that results from accumulation of lipid reactive oxygen species, marked by iron-dependent oxidative damage of phospholipids. Accumulation of iron and lipid hydroperoxides are hallmarks of ferroptosis. Diverse biological contexts, including iron handling, redox homeostasis, imbalance of lipid synthesis, participate in ferroptosis. Mechanistically, pathways of ferroptosis regulation involving System X_c^--glutathione (GSH)-glutathione peroxidase 4 (GPX4) axis, coenzyme Q10 (CoQ10)-ferroptosis suppressor protein 1 (FSP1)-ubiquinol axis, GTP cyclohydrolase 1 (GCH1)-tetrahydrobiopterin (BH4)-dihydrofolate reductase (DHFR) axis, dehydrogenase (DHODH)-ubiquinol axis have been discovered. Ferroptosis has been implicated in multiple liver diseases, such as hepatocellular carcinoma, liver ischemia-reperfusion injury, steatohepatitis, liver fibrosis, cirrhosis and liver metabolic diseases. Elucidating its mechanism offers various tractable nodes for therapeutic intervention. Here, we summarize insights into the molecular characteristics, biological processes, regulatory pathways of ferroptosis and its recent advances in the treatment of liver diseases.

Key words: ferroptosis, liver disease, lipid peroxidation

CLC Number:

R575.5

CHEN Chen, CHENG Zhuoan, WANG Cun, XIA Qiang. Research progress in ferroptosis regulation in the treatment of liver diseases[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(3): 365-373.

Figures/Tables 2

TrendMD

References 67

1	DOLMA S, LESSNICK S L, HAHN W C, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells[J]. Cancer Cell, 2003, 3(3): 285-296.
2	YANG W S, STOCKWELL B R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells[J]. Chem Biol, 2008, 15(3): 234-245.
3	DIXON S J, LEMBERG K M, LAMPRECHT M R, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072.
4	XIE Y, HOU W, SONG X, et al. Ferroptosis: process and function[J]. Cell Death Differ, 2016, 23(3): 369-379.
5	HENTZE M W, MUCKENTHALER M U, GALY B, et al. Two to tango: regulation of mammalian iron metabolism[J]. Cell, 2010, 142(1): 24-38.
6	NEMETH E, TUTTLE M S, POWELSON J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization[J]. Science, 2004, 306(5704): 2090-2093.
7	ALVAREZ S W, SVIDERSKIY V O, TERZI E M, et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis[J]. Nature, 2017, 551(7682): 639-643.
8	TERZI E M, SVIDERSKIY V O, ALVAREZ S W, et al. Iron-sulfur cluster deficiency can be sensed by IRP2 and regulates iron homeostasis and sensitivity to ferroptosis independent of IRP1 and FBXL5[J]. Sci Adv, 2021, 7(22): eabg4302.
9	DU J, WANG T, LI Y, et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin[J]. Free Radic Biol Med, 2019, 131: 356-369.
10	MA S, HENSON E S, CHEN Y, et al. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells[J]. Cell Death Dis, 2016, 7(7): e2307.
11	BROWN C W, AMANTE J J, CHHOY P, et al. Prominin2 drives ferroptosis resistance by stimulating iron export[J]. Dev Cell, 2019, 51(5): 575-586.e4.
12	YANG W H, HUANG Z Q, WU J L, et al. A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer[J]. Mol Cancer Res, 2020, 18(1): 79-90.
13	CHEN X, XU S, ZHAO C, et al. Role of TLR4/NADPH oxidase 4 pathway in promoting cell death through autophagy and ferroptosis during heart failure[J]. Biochem Biophys Res Commun, 2019, 516(1): 37-43.
14	YANG W H, DING C C, SUN T, et al. The hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma[J]. Cell Rep, 2019, 28(10): 2501-2508.e4.
15	XIE Y, ZHU S, SONG X, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity[J]. Cell Rep, 2017, 20(7): 1692-1704.
16	MURI J, KOPF M. Redox regulation of immunometabolism[J]. Nat Rev Immunol, 2021, 21(6): 363-381.
17	ZOU Y L, LI H X, GRAHAM E T, et al. Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis[J]. Nat Chem Biol, 2020, 16(3): 302-309.
18	SUZUKI T, MOTOHASHI H, YAMAMOTO M. Toward clinical application of the Keap1-Nrf2 pathway[J]. Trends Pharmacol Sci, 2013, 34(6): 340-346.
19	CONRAD M, PRATT D A. The chemical basis of ferroptosis[J]. Nat Chem Biol, 2019, 15(12): 1137-1147.
20	KAGAN V E, MAO G W, QU F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis[J]. Nat Chem Biol, 2017, 13(1): 81-90.
21	DIXON S J, WINTER G E, MUSAVI L S, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death[J]. ACS Chem Biol, 2015, 10(7): 1604-1609.
22	DOLL S, PRONETH B, TYURINA Y Y, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J]. Nat Chem Biol, 2017, 13(1): 91-98.
23	LAGROST L, MASSON D. The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease[J]. Curr Opin Lipidol, 2022, 33(3): 193-198.
24	BERSUKER K, HENDRICKS J M, LI Z P, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J]. Nature, 2019, 575(7784): 688-692.
25	DOLL S, FREITAS F P, SHAH R, et al. FSP1 is a glutathione-independent ferroptosis suppressor[J]. Nature, 2019, 575(7784): 693-698.
26	KUHN H, BANTHIYA S, VAN LEYEN K. Mammalian lipoxygenases and their biological relevance[J]. Biochim Biophys Acta, 2015, 1851(4): 308-330.
27	KRAFT V A N, BEZJIAN C T, PFEIFFER S, et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling[J]. ACS Cent Sci, 2020, 6(1): 41-53.
28	GAO M, MONIAN P, QUADRI N, et al. Glutaminolysis and transferrin regulate ferroptosis[J]. Mol Cell, 2015, 59(2): 298-308.
29	LEE H, ZANDKARIMI F, ZHANG Y L, et al. Energy-stress-mediated AMPK activation inhibits ferroptosis[J]. Nat Cell Biol, 2020, 22(2): 225-234.
30	SHIN D, LEE J, YOU J H, et al. Dihydrolipoamide dehydrogenase regulates cystine deprivation-induced ferroptosis in head and neck cancer[J]. Redox Biol, 2020, 30: 101418.
31	URSINI F, MAIORINO M, VALENTE M, et al. Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides[J]. Biochim Biophys Acta, 1982, 710(2): 197-211.
32	URSINI F, MAIORINO M, GREGOLIN C. Phospholipid hydroperoxide glutathione peroxidase[J]. Int J Tissue React, 1986, 8(2): 99-103.
33	ALIM I, CAULFIELD JT, CHEN Y, et al. Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke[J]. Cell, 2019, 177(5): 1262-1279.e25.
34	VENKATESH D, O'BRIEN N A, ZANDKARIMI F, et al. MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling[J]. Genes Dev, 2020, 34(7/8): 526-543.
35	SOULA M, WEBER R A, ZILKA O, et al. Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers[J]. Nat Chem Biol, 2020, 16(12): 1351-1360.
36	MAO C, LIU X G, ZHANG Y L, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer[J]. Nature, 2021, 593(7860): 586-590.
37	CHEN X, KANG R, KROEMER G, et al. Broadening horizons: the role of ferroptosis in cancer[J]. Nat Rev Clin Oncol, 2021, 18(5): 280-296.
38	JIANG L, KON N, LI T Y, et al. Ferroptosis as a p53-mediated activity during tumour suppression[J]. Nature, 2015, 520(7545): 57-62.
39	CHEN D, FAN Z, RAUH M, et al. ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner[J]. Oncogene, 2017, 36(40): 5593-5608.
40	WU J, MINIKES A M, GAO M H, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling[J]. Nature, 2019, 572(7769): 402-406.
41	GAO R Z, KALATHUR R K R, COTO-LLERENA M, et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis[J]. EMBO Mol Med, 2021, 13(12): e14351.
42	SINGHAL R, MITTA S R, DAS N K, et al. HIF-2α activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron[J]. J Clin Invest, 2021, 131(12): e143691.
43	HANGAUER M J, VISWANATHAN V S, RYAN M J, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition[J]. Nature, 2017, 551(7679): 247-250.
44	YANG W S, SRIRAMARATNAM R, WELSCH M E, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156(1/2): 317-331.
45	GASCHLER M M, ANDIA A A, LIU H R, et al. FINO₂ initiates ferroptosis through GPX4 inactivation and iron oxidation[J]. Nat Chem Biol, 2018, 14(5): 507-515.
46	LOUANDRE C, EZZOUKHRY Z, GODIN C, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib[J]. Int J Cancer, 2013, 133(7): 1732-1742.
47	HADIAN K, STOCKWELL B R. SnapShot: ferroptosis[J]. Cell, 2020, 181(5): 1188-1188.e1.
48	VISWANATHAN V S, RYAN M J, DHRUV H D, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway[J]. Nature, 2017, 547(7664): 453-457.
49	ELING N, REUTER L, HAZIN J, et al. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells[J]. Oncoscience, 2015, 2(5): 517-532.
50	ANGELI J P F, SCHNEIDER M, PRONETH B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice[J]. Nat Cell Biol, 2014, 16(12): 1180-1191.
51	TANG B F, ZHU J Y, LI J, et al. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma[J]. Cell Commun Signal, 2020, 18(1): 174.
52	KONG R, WANG N, HAN W, et al. IFNγ-mediated repression of system xc^-drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells[J]. J Leukoc Biol, 2021, 110(2): 301-314.
53	WU S, YANG J, SUN G L, et al. Macrophage extracellular traps aggravate iron overload-related liver ischaemia/reperfusion injury[J]. Br J Pharmacol, 2021, 178(18): 3783-3796.
54	YAMADA N, KARASAWA T, WAKIYA T, et al. Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: potential role of ferroptosis[J]. Am J Transplant, 2020, 20(6): 1606-1618.
55	LI Y, FENG D C, WANG Z Y, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion[J]. Cell Death Differ, 2019, 26(11): 2284-2299.
56	FANG X X, WANG H, HAN D, et al. Ferroptosis as a target for protection against cardiomyopathy[J]. Proc Natl Acad Sci USA, 2019, 116(7): 2672-2680.
57	ZHOU Z, YE T J, BONAVITA G, et al. Adipose-specific lipin-1 overexpression renders hepatic ferroptosis and exacerbates alcoholic steatohepatitis in mice[J]. Hepatol Commun, 2019, 3(5): 656-669.
58	LI Z Y, AGELLON L B, ALLEN T M, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis[J]. Cell Metab, 2006, 3(5): 321-331.
59	NELSON J E, WILSON L, BRUNT E M, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease[J]. Hepatology, 2011, 53(2): 448-457.
60	CHEN X, KANG R, KROEMER G, et al. Ferroptosis in infection, inflammation, and immunity[J]. J Exp Med, 2021, 218(6): e20210518.
61	YU Y, JIANG L, WANG H, et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis[J]. Blood, 2020, 136(6): 726-739.
62	ZHANG Z L, YAO Z, WANG L, et al. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells[J]. Autophagy, 2018, 14(12): 2083-2103.
63	WANG H, AN P, XIE E J, et al. Characterization of ferroptosis in murine models of hemochromatosis[J]. Hepatology, 2017, 66(2): 449-465.
64	WU A M, FENG B, YU J, et al. Fibroblast growth factor 21 attenuates iron overload-induced liver injury and fibrosis by inhibiting ferroptosis[J]. Redox Biol, 2021, 46: 102131.
65	ZAMPIERI S, MELLON S H, BUTTERS T D, et al. Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone[J]. J Cell Mol Med, 2009, 13(9b): 3786-3796.
66	VÁZQUEZ M C, BALBOA E, ALVAREZ A R, et al. Oxidative stress: a pathogenic mechanism for Niemann-Pick type C disease[J]. Oxid Med Cell Longev, 2012, 2012: 205713.
67	FU R, YANJANIN NM, BIANCONI S, et al. Oxidative stress in Niemann-Pick disease, type C[J]. Mol Genet Metab, 2010, 101(2/3): 214-218.

Inducer	Target	Inhibitor	Target
RSL3, ML162, ML210, FIN56, FINO₂	GPX4	Iron chelator	Iron toxicity
Erastin, erastin analogs, IKE, Sorafenib, Sulfasalazine, PE, glutamate, IFN-γ	System X_c^-	Ferrostatin-1, liprostatin-1, deuterated PUFAs, MUFAs	Lipid peroxidation
FIN56	CoQ10	Vitamin E, α-tocopherol, RTA	Lipid propagation
BSO	Glutamate-cysteine ligase	Thiazolidinediones	ACSL4
Statins	HMG-CoA	Baicalein, Zileuton	Lipoxygenases
Brequinar	DHODH
iFSP1	FSP1
Artemisinins	Ferritinophagy
Methotrexate	Dihydrofolate reductase

Inducer	Target	Inhibitor	Target
RSL3, ML162, ML210, FIN56, FINO₂	GPX4	Iron chelator	Iron toxicity
Erastin, erastin analogs, IKE, Sorafenib, Sulfasalazine, PE, glutamate, IFN-γ	System X_c^-	Ferrostatin-1, liprostatin-1, deuterated PUFAs, MUFAs	Lipid peroxidation
FIN56	CoQ10	Vitamin E, α-tocopherol, RTA	Lipid propagation
BSO	Glutamate-cysteine ligase	Thiazolidinediones	ACSL4
Statins	HMG-CoA	Baicalein, Zileuton	Lipoxygenases
Brequinar	DHODH
iFSP1	FSP1
Artemisinins	Ferritinophagy
Methotrexate	Dihydrofolate reductase

[1]	LIU Weiwei, WANG Long. Research progress in the correlation and treatment of menopause and non-alcoholic fatty liver disease in women [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(1): 125-131.
[2]	DU Yuting, ZHANG Jing, HUANG Ying, ZHANG Jing. Effect of ferroptosis on regeneration after muscle injury [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(3): 298-306.
[3]	Xiaowen ZHANG, Yi WANG, Chan ZHANG, Di ZHANG, Hang YUN, Di HUANG. Effects of Pcsk9 gene interference on high fat-induced nonalcoholic fatty liver disease with atherosclerosis in rats [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(2): 150-157.
[4]	Qian WEI, Ying-ting ZHANG, Long-shuai LIN, En-jun HE, Yong-yuan HE, Ying-hong SU, Cheng-cheng DUAN, Si-yuan WANG, Qing-hua ZHAO, Qian ZHAO, Ming HE. Haptoglobin suppresses hepatocyte ferroptosis via inhibition of the ERK1/2 signaling pathway [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 999-1008.
[5]	Chao SANG, Dan-dan LIANG, Guo-xiang XIE, Wei JIA, Tian-lu CHEN. Progress in serological noninvasive diagnostic methods for non-alcoholic fatty liver disease [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 112-117.
[6]	HE Ming, WEI Qian, ZHANG Ying-ting. Research progress in the mechanism of ferroptosis and its role in liver related diseases [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(11): 1519-1523.
[7]	GUO Yi-qiong, WU Qiong, WU Ya-ting, GAO Lu-lu, YANG Jian-jun. Effect of Lycium barbarum polysaccharide and aerobic exercise on rats with non-alcoholic fatty liver disease and its mechanism [J]. , 2020, 40(1): 30-.
[8]	ZHU Fan-fan, YANG Li-zhen. Correlation between the levels of serum thyroid hormones and non-alcoholic fatty liver disease in euthyroid type 2 diabetic patients [J]. , 2018, 38(7): 763-.
[9]	JIAN Chao-hui, BAO Yu-qian. Research progress of autophagy in non-alcoholic fatty liver disease [J]. , 2018, 38(6): 690-.
[10]	YING Chen1, LIU Cai-hong2, HU Jia-an2, JIANG Shi-hu3, XU Zhi-hong2, SUN Jing2. Research on level of serum lipid metabolism related hormones in patients of obstructive sleep apnoea hypoxia syndrome combine with non-alcoholic fatty liver disease [J]. , 2018, 38(10): 1203-.
[11]	HOU Ya-nan, XUAN Li-ping, PENG Kui, DU Rui, XU Yu, CHEN Yu-hong, LU Jie-li, BI Yu-fang, XU Min, WANG Wei-qing, NING Guang . Association between mid-upper arm circumference and non-alcoholic fatty liver disease or insulin resistance in middle-aged and elderly Chinese community population#br# [J]. , 2017, 37(9): 1232-.
[12]	HUANG Dong-dong, WO Lu-lu, RUAN Xin, XU Ya-qian, GONG Yi-ming, YANG Lin-xi, LI Xue-chuan, KANG Yue-ning, HE Ming . Construction of a new alcoholic liver disease mouse model [J]. , 2017, 37(7): 906-.
[13]	ZHANG Zhen-zhen, CHEN Zheng, YUAN Qing-qing, SUN Min, NIU Ming-hui, HE Zu-ping. Application of hepatic stem cells and spermatogonial stem cells in treatment of liver disease [J]. , 2016, 36(9): 1351-.
[14]	SUN Wen-wen, RUAN Yu-feng， LIAN Peng, YING Chen, HU Jia-an, XU Zhi-hong, SUN Jing. Effects of obstructive sleep apnoea syndrome on non-alcoholic fatty liver disease [J]. , 2016, 36(5): 707-.
[15]	CANG Zhen, ZHU Chao-xia, Jiazireya·Zaiyinati, et al. Isotope labeling experiment of fatty acid oxidation in gastrocnemius of rats with nonalcoholic fatty liver [J]. , 2015, 35(6): 789-.